960 reports of this reaction
3.2% of all ZIPRASIDONE MESYLATE reports
#2 most reported adverse reaction
DIABETES MELLITUS is the #2 most commonly reported adverse reaction for ZIPRASIDONE MESYLATE, manufactured by ROERIG. There are 960 FDA adverse event reports linking ZIPRASIDONE MESYLATE to DIABETES MELLITUS. This represents approximately 3.2% of all 30,183 adverse event reports for this drug.
Patients taking ZIPRASIDONE MESYLATE who experience diabetes mellitus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIABETES MELLITUS is moderately reported among ZIPRASIDONE MESYLATE users, representing a notable but not dominant share of adverse events.
In addition to diabetes mellitus, the following adverse reactions have been reported for ZIPRASIDONE MESYLATE:
The following drugs have also been linked to diabetes mellitus in FDA adverse event reports:
DIABETES MELLITUS has been reported as an adverse event in 960 FDA reports for ZIPRASIDONE MESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIABETES MELLITUS accounts for approximately 3.2% of all adverse event reports for ZIPRASIDONE MESYLATE, making it one of the most commonly reported side effect.
If you experience diabetes mellitus while taking ZIPRASIDONE MESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.